<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234581</url>
  </required_header>
  <id_info>
    <org_study_id>1185</org_study_id>
    <nct_id>NCT04234581</nct_id>
  </id_info>
  <brief_title>The Effect of Lysulin on Glycemic Control and Advanced Glycation</brief_title>
  <official_title>The Effect of Lysulin on Glycemic Control and Advanced Glycation in Inadequately Controlled Type 2 Diabetes Mellitus: a Double Blinded Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juraj Koska</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl T. Hayden VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether 12 weeks of treatment with Lysulin, compared to
      placebo, causes a reduction from baseline in the plasma levels of glucose, hemoglobin A1c
      (HbA1c) and Advanced Glycation Endproducts (AGEs) in patients with inadequately controlled
      type 2 diabetes mellitus. Secondary objectives include determining whether 12 weeks of
      treatment with Lysulin increases beta-cell function as measured by plasma C-peptide levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective(s): The primary objective is to determine whether 12 weeks of treatment with
      Lysulin, compared to placebo, causes a reduction from baseline in the plasma levels of
      glucose, hemoglobin A1c (HbA1c) and Advanced Glycation Endproducts (AGEs) in patients with
      inadequately controlled type 2 diabetes mellitus. Secondary objectives include determining
      whether 12 weeks of treatment with Lysulin increases beta-cell function as measured by plasma
      C-peptide levels.

      Research Plan: A randomized, prospective, double-blind study with randomization to lysulin
      and placebo in a 1:1 fashion. The study will enroll 60 patients with inadequately controlled
      type 2 diabetes.

      Methods: The study will be performed as outpatient study at Phoenix VA Clinical Research
      Center. The study will include 3-4 visits. At the initial visit, participants will complete
      informed consent proc HbA1c ≥ 7.5 % and &lt; 10%ess and undergo screening examination. Inclusion
      criteria will be age 21-75 years, HbA1c ≥ 7.5 % and &lt; 10%, and stable dose of insulin 6 weeks
      prior to enrollment. Qualified participants will be randomized to 3,330 mg/day Lysulin (1,110
      mg tbl, TID) as add-on supplement therapy for 12 weeks. Follow-up visits will be at weeks 6
      and week 12 (end of study). Baseline and follow-up visits will include physical examination,
      patient history and blood draw. The primary study outcome measure will be fasting plasma
      glucose and HbA1c. Secondary outcome measures will include fasting plasma C-peptide and AGE
      concentrations. A linear mixed effects model will be used to evaluate treatment-induced
      endpoints. The models will be fit for sequential values of the response variable (including
      the baseline measurement).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>Baseline</time_frame>
    <description>Hemoglobin A1c measured by PVAHS pathology lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hemoglobin A1c measured by PVAHS pathology lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting C-peptide</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma C-peptide measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting C-peptide</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma C-peptide measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CML</measure>
    <time_frame>Baseline</time_frame>
    <description>Nɛ-carboxymethyl lysine in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CML</measure>
    <time_frame>12 weeks</time_frame>
    <description>Nɛ-carboxymethyl lysine in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEL</measure>
    <time_frame>Baseline</time_frame>
    <description>Nɛ-carboxyethyl lysine in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Nɛ-carboxyethyl lysine in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH1</measure>
    <time_frame>Baseline</time_frame>
    <description>Glyoxal hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glyoxal hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3DGH1</measure>
    <time_frame>Baseline</time_frame>
    <description>3-deoxyglucosone hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3DGH1</measure>
    <time_frame>12 weeks</time_frame>
    <description>3-deoxyglucosone hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGH1</measure>
    <time_frame>Baseline</time_frame>
    <description>Methylglyoxal hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGH1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Methylglyoxal hydroimidazolone in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MetSO</measure>
    <time_frame>Baseline</time_frame>
    <description>Methionine sulfoxide in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MetSO</measure>
    <time_frame>12 weeks</time_frame>
    <description>Methionine sulfoxide in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-AAA</measure>
    <time_frame>Baseline</time_frame>
    <description>2-aminoadipic acid in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-AAA</measure>
    <time_frame>12 weeks</time_frame>
    <description>2-aminoadipic acid in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Lysulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lysulin</intervention_name>
    <description>Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.</description>
    <arm_group_label>Lysulin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  HbA1c ≥7.5% and &lt;10.0% within past 6 weeks on diet only or stable doses of oral
             antihyperglycemic agents with or without insulin

          -  stable body weight (&lt; 5% change in last 3 months)

          -  If on insulin therapy: &lt; 20% variation in insulin units 6 weeks prior to the study.

        Exclusion Criteria:

          -  Type 1 DM

          -  current or recent use of supplements containing lysine, zinc or vitamin C

          -  uncontrolled hypertension (blood pressure ≥160/90 mmHg)

          -  kidney disease (serum creatinine GFR ≤50 mL/min)

          -  major illness

          -  severe gastrointestinal disease

          -  pregnancy

          -  liver function tests &gt; 2.5 times normal values in the past 3 months

          -  currently abusing alcohol or drugs, or have a history of alcohol or drug abuse that in
             the investigator's opinion could cause the subject to be non-compliant; or have a
             general history of non-compliance with medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix VA Healthcare System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Thompson, Dr.</last_name>
      <phone>602-277-5551</phone>
      <phone_ext>6697</phone_ext>
      <email>david.thompson4@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix VA Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michell Sorley, RN</last_name>
      <phone>602-277-5551</phone>
      <phone_ext>7063</phone_ext>
      <email>michell.sorley@va.gov</email>
    </contact>
    <investigator>
      <last_name>Juraj Koska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter D Reaven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carl T. Hayden VA Medical Center</investigator_affiliation>
    <investigator_full_name>Juraj Koska</investigator_full_name>
    <investigator_title>Senior Research Health Scientist</investigator_title>
  </responsible_party>
  <keyword>lysine</keyword>
  <keyword>vitamin C</keyword>
  <keyword>zinc</keyword>
  <keyword>hemoglobin A1c</keyword>
  <keyword>advanced glycation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available on request. To protect the privacy and confidentiality of the research subjects, data will be de-identified by stripping all 18 HIPAA identifiers as comma-delimited text (.csv) files to ensure it is impossible to back out any changes and recover identifiable information.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

